methohexital sodium (brevital sodium) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Methohexital is an ultrashort-acting barbiturate widely used in dentistry because of its rapid onset, predictable effects, and short duration of action. It was marked under the name brevital sodium for the intravenous anaesthesia. It has also been commonly used to induce deep sedation. Like other barbiturates, methohexital exerts its effects through the gamma-aminobutyric acid (GABA) receptor complex. By binding to its own receptor on the complex, methohexital augments the inhibitory effect of GABA on neurons and additionally can exert a similar effect independent of GABA.   NCATS

Chemistry

  • SMILES: C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O
  • InChIKey: NZXKDOXHBHYTKP-UHFFFAOYSA-N
  • Mol. Mass: 262.31
  • ALogP: 1.31
  • ChEMBL Molecules:
    methohexital  
    methohexital sodium  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.9172
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1h,3h,5h)-pyrimidinetrione | (+-)-5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid | 5-allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione | 5-allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid | alpha-dl-1-methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid | brevimytal | brevital | brevital sodium | brietal | brietal sod | enallynymall | enallynymal sodium | methodrexitone | methohexital | methohexital sodium | methohexitalum | methohexitone | metoesital | metohexital

Organizations (13)

Research & Development (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Pain (approved 1960)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Atrial Fibrillation (Phase 4)

Atrial Flutter (Phase 4)

Bipolar Disorder (Phase 4)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Electroconvulsive Therapy (Phase 4)

Encephalitis (Early Phase 1)

Ketamine (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial Organizations: 12

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue